Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EBT (2022 - 2025)

TriSalus Life Sciences' EBT history spans 4 years, with the latest figure at -$9.8 million for Q4 2025.

  • For Q4 2025, EBT rose 3.52% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$39.2 million, down 30.56%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • EBT reached -$9.8 million in Q4 2025 per TLSIW's latest filing, up from -$10.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $2.8 million in Q1 2022 to a low of -$35.6 million in Q4 2023.
  • Average EBT over 4 years is -$9.6 million, with a median of -$9.0 million recorded in 2025.
  • The largest YoY upside for EBT was 82.39% in 2023 against a maximum downside of 678.23% in 2023.
  • A 4-year view of EBT shows it stood at -$22.5 million in 2022, then plummeted by 58.14% to -$35.6 million in 2023, then skyrocketed by 71.63% to -$10.1 million in 2024, then grew by 3.52% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's EBT are -$9.8 million (Q4 2025), -$10.8 million (Q3 2025), and -$8.3 million (Q2 2025).